Lymphoma Clinical Trials in Illinois

Showing 461-480 of 564 trials

Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT01278615

This phase II clinical trial is studying how well selumetinib works in treating patients with relapsed or refractory diffuse large B-cell lymphoma. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Recurrent Adult Diffuse Large Cell Lymphoma

National Cancer Institute (NCI)16 participantsStarted Dec 2010

Chicago, Illinois, United States • Chicago, Illinois, United States • Decatur, Illinois, United States +13 more locations

COMPLETEDPhase 340 miles

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

NCT00058331

RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with solid tumors. It is not yet known whether epoetin alfa given once a week is more effective than epoetin alfa given once every 3 weeks in treating anemia. PURPOSE: Randomized phase III trial to study the effectiveness of epoetin alfa in treating anemia in patients who have solid tumors.

AnemiaLeukemiaLymphoma+4 more

Alliance for Clinical Trials in Oncology365 participantsStarted Jun 2003

Scottsdale, Arizona, United States • Jacksonville, Florida, United States • Peoria, Illinois, United States +15 more locations

Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

Lymphoma Trials in Other Cities

Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma

Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss

A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)

Imexon for Relapsed Follicular and Aggressive Lymphomas

A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13

Other Conditions in Illinois